Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Crinetics Pharmaceuticals Inc (NQ: CRNX )

56.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crinetics Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is Tenon Medical (TNON) Stock Down 30% Today?
Tenon Medical (TNON) stock is falling on Monday after the surgical implant company announced a proposed public offering for its shares. 
Via InvestorPlace
Why Is Versus Systems (VS) Stock Up 17% Today?
Versus Systems (VS) stock is rising higher on Monday as the business software company's shares experience heavy trading this morning. 
Via InvestorPlace
Why Tenon Medical Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Is Crinetics Pharmaceuticals (CRNX) Stock Up 64% Today?
Crinetics Pharmaceuticals (CRNX) stock is on the rise Monday after the company announced positive clinical trial results. 
Via InvestorPlace
9 Analysts Have This to Say About Crinetics Pharmaceuticals
Via Benzinga
Analyst Expectations for Crinetics Pharmaceuticals's Future
Via Benzinga
Where Crinetics Pharmaceuticals Stands With Analysts
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the workweek right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Crinetics Pharmaceuticals
Via Benzinga
Crinetics Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Biotech Stock Crinetics Pharmaceuticals Positioned For Success In Chronic Endocrine Disorder Treatment, Says Analyst
Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) with an Outperform rating  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
Via Benzinga
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics to Highlight Broad Pipeline at ENDO 2023
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship 
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Via Benzinga
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.